[Synthesis of phosphoramide mustard analogues belonging to the L-sugar series]. 2001

A Csorvási, and E K Katalin, and F Sztaricskai
Debreceni Egyetem Gyógyszerészi Kémiai Tanszék és MTA Antibiotikum-kémiai Kutatócsoport, Debrecen, Pf. 70.-H-4010.

During the past decades numerous cyclophoshamide (mustard) derivatives of nucleosides and aminodeoxy sugars have been prepared for investigating their antitumor activities. The cyclophosphamide analogues of aminotrideoxy hexoses belonging to the D-series of sugars have been prepared by Monneret et al. The present paper reports the synthesis of the new phosphoramide mustards 16-17 from 12 and 15 (belonging to the L-sugar series). First compound 10 was synthesized from the L-rhamnose (9). Methyl 3-azido-2,3,6,-trideoxy-alpha-L-ribo-hexopyranoside (11) was obtained by the replacement of the 3-O-p-toluene-sulfonyl group of 10 with sodium azide. Methyl 3-azido-2,3,6,-trideoxy-alpha-L-arabino-hexopyranoside (14) was synthesized by rign opening of 13 with sodium azide. The corresponding amino sugars (12, 15) were obtained by catalytic hydrogenation (over palladium on carbon) of 11 and 14. Our compounds 12 and 15 were transformed into the cyclophosphamide derivatives 16a,b-17a,b upon treatment with bis(2-chloroethyl)phoshoramidic dichloride in the presence of triethylamine (36 h, r.t.). The approximately 1:1 mixtures of isomers (due to the different steric position of the P=O group) could be readily separated by chromatography. The 1H NMR assignments of compounds 16a, 16b, 17a and 17b, were based on one-dimensional selective decoupling experiments or two-dimensional chemical shift-correlated spectroscopy (COSY-60). The assignment of configuration to the isomeric phosphoramidates was based on the magnetic anisotropy of the P=O bond. The distinctly different chemical shift patterns of sugar protons observed for the two isomers allowed the unambiguous assignment of the P=O stereochemistry. The compounds 16a,b-17a,b (mixture of isomers) were tested for inhibitory activity using L1210 and HT29 cell lines.

UI MeSH Term Description Entries
D007202 Indicators and Reagents Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499) Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D010752 Phosphoramide Mustards A group of nitrogen mustard compounds which are substituted with a phosphoramide group or its derivatives. They are usually cytotoxic and used as antineoplastic agents. Mustards, Phosphoramide
D006601 Hexoses MONOSACCHARIDES whose molecules contain six carbon atoms, such as GLUCOSE and FRUCTOSE. They generally have the chemical formula C6H12O6. Hexose
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D018906 Antineoplastic Agents, Alkylating A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) Alkylating Agents, Antineoplastic,Alkylating Antineoplastic Agents,Alkylating Antineoplastic Drugs,Alkylating Antineoplastics,Alkylating Drugs, Antineoplastic,Antineoplastic Alkylating Agents,Antineoplastic Drugs, Alkylating,Antineoplastics, Alkylating,Antineoplastic Alkylating Drugs,Drugs, Antineoplastic Alkylating

Related Publications

A Csorvási, and E K Katalin, and F Sztaricskai
September 1998, Archiv der Pharmazie,
A Csorvási, and E K Katalin, and F Sztaricskai
November 1980, Journal of medicinal chemistry,
A Csorvási, and E K Katalin, and F Sztaricskai
January 2017, Reproductive toxicology (Elmsford, N.Y.),
A Csorvási, and E K Katalin, and F Sztaricskai
March 1976, Cancer research,
A Csorvási, and E K Katalin, and F Sztaricskai
June 1995, Journal of medicinal chemistry,
A Csorvási, and E K Katalin, and F Sztaricskai
November 1993, Journal of medicinal chemistry,
A Csorvási, and E K Katalin, and F Sztaricskai
December 2017, ACS medicinal chemistry letters,
A Csorvási, and E K Katalin, and F Sztaricskai
December 1985, Journal of pharmaceutical sciences,
A Csorvási, and E K Katalin, and F Sztaricskai
November 1980, Cancer research,
A Csorvási, and E K Katalin, and F Sztaricskai
April 2022, ACS infectious diseases,
Copied contents to your clipboard!